Prosensa is a biotechnology company engaged in the discovery, development and commercialization of RNA-modulating therapeutics . The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy and Huntington's disease.

Private Funding Events

DateOfferedSoldType
2014-12-08$50,488,095$50,488,095Debt, Option to Acquire

Contact Information

    Key Executives

    • Hans Schikan
      Executive Officer
    • Giles Campion
      Executive Officer
    • Berndt Modig
      Executive Officer
    • Luc Dochez
      Executive Officer
    • Peter Goodfellow
      Director
    • David Mott
      Director
    • Daan Ellens
      Director
    • Martijn Kleijwegt
      Director
    • Annalisa Jenkins
      Director
    • Michael Wyzga
      Director
    • Georges Gemayel
      Director